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The gastrin releasing peptide receptor (GRPR) and the somatostatin receptor 2 (SSTR2)
are overexpressed on primary breast cancer (BC), making them ideal candidates for recep-
tor-mediated nuclear imaging and therapy. The aim of this study was to determine whether
these receptors are also suitable targets for metastatic BC.
Methods
mRNA expression of human BC samples were studied by in vitro autoradiography and asso-
ciated with radioligand binding. Next, GRPR and SSTR2 mRNA levels of 60 paired primary
BCs and metastases from different sites were measured by quantitative reverse transcrip-
tase polymerase chain reaction. Receptor mRNA expression levels were associated with
clinico-pathological factors and expression levels of primary tumors and corresponding
metastases were compared.
Results
Binding of GRPR and SSTR radioligands to tumor tissue correlated significantly with recep-
tor mRNA expression. High GRPR and SSTR2 mRNA levels were associated with estrogen
receptor (ESR1)-positive tumors (p<0.001 for both receptors). There was no significant dif-
ference in GRPR mRNA expression of primary tumors versus paired metastases. Regard-
ing SSTR2 mRNA expression, there was also no significant difference in the majority of
cases, apart from liver and ovarian metastases which showed a significantly lower expres-
sion compared to the corresponding primary tumors (p = 0.02 and p = 0.03, respectively).
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Conclusion
Targeting the GRPR and SSTR2 for nuclear imaging and/or treatment has the potential to
improve BC care in primary as well as metastatic disease.
Introduction
Breast cancer (BC) is the second most common cancer found in women and the fifth cause of
cancer related death [1]. The disease is very heterogeneous. Different subtypes with distinctive
morphological and molecular characteristics exist. The four major intrinsic BC subtypes are
luminal A, luminal B, human epidermal growth factor 2 (HER2, ERBB2)-driven and basal-like
BC [2, 3]. Treatment and prognosis of the disease are highly dependent on these subtypes;
luminal A and luminal B tumors have a better prognosis than basal-like BC [2, 3]. Although
multiple therapy options for BC exist, 20–30% of BC patients experience relapse with meta-
static disease [4].
Peptide receptor mediated nuclear imaging and peptide receptor radionuclide therapy are
methods successfully used in the clinic for imaging and treatment of neuroendocrine tumors
[5]. These methods are based on targeting receptors that are overexpressed on cancer cells
using radiolabeled peptide analogs. Regarding BC, multiple studies have demonstrated overex-
pression of the gastrin releasing peptide receptor (GRPR) and the somatostatin receptor 2
(SSTR2). In line with this, several pre-clinical as well as clinical studies demonstrated feasibility
of imaging and/or treatment of BC with GRPR and SSTR2 radioligands with promising
results, and indicated specific BC patients groups that can benefit from the application of these
radioligands [6–10].
However, previous studies were solely based on primary BC while BC-related death is
largely caused by metastatic disease. Targeting the GRPR and SSTR2 could thus especially be
advantageous for treatment of metastatic BC.
In this study, we examined the GRPR and SSTR2mRNA expression levels of primary
tumors and paired metastases, in order to evaluate whether nuclear imaging and therapy
might also be beneficial for metastatic BC.
Materials and Methods
Human BC cases
Retrospectively, we selected 74 formalin-fixed paraffin-embedded (FFPE) primary BCs and 77
corresponding metastases from an existing database of the University Medical Center Utrecht
and from the pathology archive of the Erasmus Medical Center [11, 12]. Fresh frozen (FF) tis-
sue of 6 paired primary tumors and regional lymph node metastases were also included. Each
specimen was reviewed by a pathologist (CHMvD) to confirm the presence of malignancy and
to determine the percentage of tumor cells (cut-off point of>50% tumor cells). Inclusion crite-
ria were: availability of clinico-pathological data, the presence of enough tumor tissue and
good RNA quality to reliably determine RT-qPCR levels (see below). After applying these
inclusion criteria, 68 primary tumors and 60 metastases remained, resulting in 60 paired pri-
mary BCs and metastases from different sites, including brain (n = 12), regional lymph nodes
(n = 20), liver (n = 10), ovary (n = 5), lung (n = 5) and other sites (n = 8, consisting of bone
(n = 2), uterus (n = 1), gastrointestinal tract (n = 2) and distant lymph node metastases
(n = 3)). Clinico-pathological characteristics included age, primary tumor size, histological
GRPR and SSTR2 in Breast Cancer Metastases
PLOS ONE | DOI:10.1371/journal.pone.0170536 January 20, 2017 2 / 12
This does not alter our adherence to PLOS ONE
policies on sharing data and materials.
subtype, histological grade according to Bloom & Richardson [13], estrogen receptor (ER,
ESR1) status, ERBB2 status, and regional lymph node status.
Approval for the use of tissue samples was obtained from the Erasmus MC Medical Ethical
Committee (MEC02953) and adhered to the Code of Conduct of the Federation of Medical
Scientific Societies in The Netherlands.
RNA isolation and quantitative reverse transcriptase polymerase chain
reaction (RT-qPCR)
Ten 10 μm slides were cut from the FFPE and 10×20 μm from the FF primary BCs and paired
metastases. The first and last sections (5 μm) were stained with hematoxylin and eosin to guide
macro-dissection of the tumor cells for RNA extraction. Total RNA was isolated from the
macro-dissected FFPE sections with the AllPrep DNA/RNA FFPE Kit (Qiagen) and from the
FF sections with RNA-B (Campro Scientific) according the manufacturer’s instructions.
Nucleic acid concentrations were measured with a Nanodrop 1000 system. cDNA was gener-
ated for 30 min at 48˚C with RevertAid H minus (ThermoFisher Scientific) and gene-specific
pre-amplified with Taqman PreAmp Master mix (ThermoFisher Scientific) for 15 cycles, fol-
lowed by Taqman probe—based real time PCRs according the manufacturer’s instructions in
a MX3000P Real-Time PCR System (Agilent). The following gene expression assays were eval-
uated (all from ThermoFisher Scientific): GRPR, Hs01055872 m1; SSTR2, Hs0099356 m1;
ESR1, Hs00174860_m1; ERBB2, Hs01001580_m1, and quantified relative to the average
expression of GUSB, Hs9999908_m1; HMBS, Hs00609297_m1 and TBP, Hs00427620_m1
using the delta Cq method (dCq = 2ˆ(average Cq reference genes—Cq target gene)). Samples
that resulted in amplifiable products within 25 cycles for this reference gene set at an input of
50 ng total RNA (91.2% of the samples) were considered to be of good quality to reliably deter-
mine RT-qPCR levels. Additional quality and quantity control measurements that were taken
to ensure reliable RT-qPCR data analysis are described in the Supplemental Methods in
S1 File.
In this study, we used ESR1 and ERBB2mRNA expression levels to determine ESR1 and
ERBB2 status (using a cut-off dCq for ESR1>1 and ERBB2>3.5 by optimal binning for n = 92
and n = 87 overlapping samples, respectively (See S1 File).
Radioligands and in vitro autoradiography
The radiolabeled GRPR antagonist, JMV4168 [14], and the radiolabeled SSTR2 agonist,
DOTA-Tyr3-octreotate (Mallinckrodt) were radiolabeled with 111In (Covidien) using quench-
ers to prevent radiolysis as previously described [15, 16]. Specific activity was 80 MBq/nmol
for both radiotracers. Radiochemical purity and radiometal incorporation, measured by
instant thin-layer chromatography on silica gel and high-pressure liquid chromatography as
previously described, were>90% [16].
Slides (10 μM) of FF primary BC and paired metastases (n = 6 each) were used for autoradi-
ography experiments. Tissue sections were incubated with 100 μL incubation buffer (167 mM
Tris-HCL, 5 mM MgCl2, 1% BSA) containing 10−9 M of the radiolabeled peptide for 1 h, with
and without 10−6 M unlabeled tracer to determine specificity of binding. Results of the autora-
diography experiments were quantified using Optiquant (Perkin Elmer) and the percentage
added dose (%AD) of the radioligand bound to the tumor tissue was used as an indirect mea-
surement for the level of protein expression. Radioligand binding to primary tumors and
paired metastasis was compared and correlated with the measured GRPR and SSTR2mRNA
expression levels in corresponding FF tumor material. Furthermore, mRNA receptor expres-
sion measured in FF tumor material was correlated with mRNA receptor expression measured
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from FFPE tumor material of the same tumor. These correlation analyses were performed to
demonstrate that mRNA expression of FFPE material could be used as a surrogate for radio-
tracer binding. The autoradiography experiments and quantification of the results were per-
formed as described in the Supplemental Methods in S1 File.
Statistics
For the analysis, the STATA statistical package v14.1 and SPSS version 23 were used. Variables
were checked for normality prior to analysis. To compare mean values between two or more
groups, the Student t-test or analysis of variance ANOVA were used. To compare values for
primary and metastatic disease the paired t-test was applied. Pearson and Spearman correla-
tions were calculated when appropriate. P0.05 were considered statistically significant.
Results
In vitro autoradiography
Six pairs of primary BCs and regional lymph node metastases (n = 12 samples) with varying
mRNA receptor expression were analyzed for their ability to bind the GRPR radioligand,
111In-JMV4168, and the SSTR2 radioligand, 111In-DOTA-Tyr3-octreotate, using in vitro auto-
radiography. Fig 1A shows the in vitro autoradiography results of the paired samples. From
the six paired samples analyzed, two cases showed specific binding of the GRPR and SSTR2
radioligands in both the primary tumor and the lymph node metastases. In two cases there
was no binding of the GRPR radioligand and in three cases there was no binding of the SSTR2
radioligand in both the primary tumors and the lymph node metastases. In two cases binding
of the GRPR radioligand was observed in the primary tumor but not in the lymph node metas-
tasis, while in one case binding of the SSTR2 radioligand was observed in the lymph node
metastasis, but not in the primary tumor.
When the %AD of the radiotracer bound to the FF tumor tissue was correlated with the
mRNA receptor expression of the FF tumor material, a significant positive correlation was
found for both GRPR (Spearman rs = 0.83, p = 0.0008) and SSTR2 (Spearman rs = 0.87,
p = 0.0003) (Fig 1B+1D). Furthermore, correlation analysis of mRNA receptor expression lev-
els quantified in FF and FFPE material of the same tumor, resulted in a significant positive cor-
relation for both GRPR (Spearman rs = 0.77, p = 0.0034) and SSTR2 (Spearman rs = 0.72,
p = 0.0082) (Fig 1C+1E).
Association of GRPR and SSTR2 mRNA expression with clinico-
pathological factors
Table 1 and S2 File show the patient characteristics, including the association of GRPR and
SSTR2mRNA expression of primary BCs with clinico-pathological factors. High GRPR
mRNA expression levels were significantly associated with low histologic grade, lobular sub-
type, ESR1-positive and ERBB2-negative tumors. High SSTR2mRNA expression levels were
also significantly associated with lobular subtype and ESR1-positive tumors.
GRPR and SSTR2mRNA expression levels of the metastases were correlated with ESR1 and
ERBB2 expression of the metastasis itself (Table 2). Similar to the primary tumors, high GRPR
and SSTR2mRNA levels were significantly associated with ESR1-positive metastases. Further-
more, high GRPR mRNA status was significantly associated with ERBB2-negative metastases.
Unlike the primary tumors, high SSTR mRNA levels were significantly associated with ERBB2-
negative metastatic lesions.
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Fig 1. In vitro autoradiography of primary BC and corresponding regional lymph node metastases. A.
Hematoxylin and eosin (H&E) staining and autoradiography results after incubating cells with the GRPR
radioligand, 111In-JMV4168, and the SSTR2 radioligand, 111In-DOTA-Tyr3-octreotate. B+D. Correlation of
quantified autoradiography results (% AD) with mRNA expression of fresh frozen (FF) tissue. C+E.
Correlation of mRNA expression of FF and formalin fixed paraffin embedded (FFPE) tissue of the same
tumor.
doi:10.1371/journal.pone.0170536.g001
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GRPR and SSTR2 mRNA expression of primary BC vs. corresponding
metastases
Fig 2 shows the box plots of GRPR and SSTR2mRNA expression in primary tumors and corre-
sponding metastases.
Comparison of receptor mRNA expression levels of primary tumors and corresponding
metastases showed no significant difference in GRPR mRNA levels between primary tumors
Table 1. Association of GRPR and SSTR2 mRNA expression with clinico-pathological factors of primary BC a.
Characteristic No of patients Percentage of patients GRPR mRNA log2 SSTR2 mRNA log2
Mean SD Mean SD
All patients in this cohort 68 100 -2.90 3.8 -2.51 2.15
Age at surgery (years) b
 40 11 16 -1.63 4.02 -2.23 2.13
41–55 27 39 -1.96 3.75 -2.08 2.38
56–70 22 32 -4.96 2.85 -3.07 1.94
> 70 7 10 -2.72 4.32 -2.90 2.04
P 0.08 0.22
Tumor size c
 2 cm 25 36 -2.62 3.97 -2.61 2.24
2 5 cm 29 42 -3.47 3.44 -2.32 2.16
> 5 cm 10 14 -2.00 4.22 -2.95 2.09
P 0.51 0.72
Histopathological subtype d
Ductal 55 80 -3.34 3.76 -2.82 2.15
Lobular 11 16 -0.80 3.44 -1.04 1.74
Other 2 3 -2.38 3.72 -2.04 1.26
P 0.04 0.01
Bloom & Richardson grade e
I + II 15 22 -1.23 3.57 -1.80 2.20
III 44 64 -3.66 3.91 -2.88 2.18
P 0.04 0.12
ESR1 status e
Negative 25 36 -6.52 1.68 -3.83 2.09
Positive 42 61 -0.79 3.04 -1.79 1.80
P <0.001 <0.001
ERBB2 status e
Negative 46 67 -2.12 3.60 -2.44 2.26
Positive 11 16 -5.04 2.62 -2.7 2.23
P 0.006 0.73
Regional lymph node status e
Negative 15 22 -4.40 3.06 -2.96 2.33
Positive 44 64 -2.67 4.02 -2.48 2.01
p 0.13 0.44
a Due to missing values numbers don’t always add up to 68
b Receptor expression of ductal BC and lobular BC was compared using the student t-test.
c P for Pearson correlation.
d P for variance of ANOVA.
e P for student t-test.
doi:10.1371/journal.pone.0170536.t001
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and corresponding regional lymph node and distant metastases in the brain, lung, liver and
ovaries. However, in the group of metastases from other sites, GRPR mRNA expression levels
were significantly lower in the metastases compared to the corresponding primary BC
(p = 0.02).
Regarding SSTR2mRNA levels, there were no significant differences in SSTR2mRNA
expression of the primary tumor and the paired metastasis in regional lymph nodes, brain,
lung and other locations. However, SSTR2mRNA levels of liver and ovarian metastases were
significantly lower compared to the expression in the corresponding primary BC (p = 0.02 and
p = 0.03, respectively).
Next, we compared the receptor mRNA expression levels between distant metastases from
various metastatic sites amongst each other. GRPR mRNA levels were significantly higher in
the ovarian metastases (p = 0.03), while there were no significant differences in SSTR2mRNA
expression levels in distant metastases from different sites.
In some cases studied (n = 11), there was a discordance regarding ESR1 status of primary
BCs and corresponding metastases. When studying the effect of change in ESR1 status on
receptor mRNA expression in primary tumors and paired metastasis, GRPR and SSTR2
mRNA expression changed accordingly (higher GRPR/SSTR2mRNA expression in ESR1-posi-
tive lesions compared to ESR1-negative lesions) in the majority of the tumors. However, this
difference was only significant (p<0.05) for ESR1-positive primary BCs with corresponding
ESR1-negative metastases (n = 6). Discordance regarding ERBB2 status was seen in 6 paired
samples. In these samples a change in ERBB2 status of primary BCs and corresponding metas-
tases did not have a consistent effect on GRPR mRNA expression levels.
Discussion
Targeting of GRPR and SSTR2 overexpressed on BC cells with radioligands can offer novel
imaging and therapy options for BC. Previous clinical and preclinical studies reported promis-
ing results. However, these studies were restricted to primary BC, while metastases are the
main cause of BC-related death. In this study, we compared GRPR and SSTR2mRNA
Table 2. Association of receptor mRNA expression with ESR1 and ERBB2 status in BC metastases.
ER status a ERBB2 status a
Negative Positive p Negative Positive p
Mean SD Mean SD Mean SD Mean SD
All metastases
No of patients 24 35 48 11
GRPR -6.26 2.76 -1.87 3.90 <0.001 -2.67 3.77 -7.98 2.15 <0.001
SSTR2 -3.95 1.64 -2.89 2.23 0.04 -2.91 1.96 -5.11 1.49 <0.001
Regional lymph node metastases
No of patients 4 16 16 4
GRPR -7.0 1.96 -1.70 3.53 0.003 -1.70 3.54 -7.02 1.84 0.002
SSTR2 -4.03 0.97 -2.92 2.67 0.20 -2.77 2.47 -4.62 1.92 0.16
All distant metastases b
No of patients 20 19 32 7
GRPR -6.12 2.92 -2.01 4.27 0.001 -3.15 3.84 -8.52 2.26 <0.001
SSTR2 -3.94 1.76 -2.86 1.85 0.07 -2.98 1.69 -5.40 1.26 0.001
a P for student t-test.
b Numbers do not add up to 60 because for 1 patient ESR1 and ERBB2 were unknown.
doi:10.1371/journal.pone.0170536.t002
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expression levels in a unique dataset of primary BC and corresponding metastases to deter-
mine whether receptor-based imaging and/or therapy could also be useful for metastatic BC.
For this purpose, we selected FFPE material of primary BCs and corresponding metastases
from different sites, and compared mRNA receptor expression levels of the paired samples.
Fig 2. GRPR and SSTR2 mRNA levels in primary BC (PBC) and corresponding metastases (BCM).
Significant differences are indicated by *.
doi:10.1371/journal.pone.0170536.g002
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Prior to this, we evaluated whether mRNA expression levels of tumor tissue properly represent
radioligand binding, by correlating in vitro autoradiography results with mRNA expression
levels of selected primary tumors and corresponding metastases with varying mRNA receptor
expression. In line with previously published findings [10], we demonstrated that there was a
high correlation between mRNA expression of the receptors and radiotracer binding, which
suggests that mRNA expression levels can be used as a surrogate for radiotracer binding.
Next, we determined the GRPR and SSTR2mRNA expression of the paired primary BCs
and metastases. When we associated receptor mRNA expression levels of primary BCs and
metastases with clinico-pathological factors, we observed a significantly higher GRPR and
SSTR2 expression in both ESR1-positive primary BC and metastases. These findings are in
agreement with our previous findings [10] and findings by Kumar et. al. [17] and Stoykow
et al. [7]. The latter publication describes a clinical study in which the GRPR radioligand,
68Ga-RM2 was successfully used for imaging of BC lesions and imaging success-rate associated
positively with ER and PR status. Furthermore, Prignon et al. [18] demonstrated that 68Ga-
AMBA, a GRPR agonist, was better suited for monitoring response to hormonal treatment
than 18F-FDG PET in an ER-positive BC model. In another study, van den Bossche et al.[19]
published data indicating an estrogen-dependent regulation of SSTR expression in BC cell
lines. Since ER-positive BC accounts for approximately 75% of the BC population, applying
receptor targeted nuclear imaging and/or therapy using GRPR or SSTR2 radioligands could be
beneficial for the majority of the BC population [2].
In paired primary tumors and metastases a change in ESR1 expression from positive to neg-
ative resulted in a significant decrease in GRPR and SSTR2mRNA levels. This may indicate an
ESR1 dependent expression of GRPR and SSTR2, which is consistent with literature [19, 20].
Difference in ERBB2 status in primary tumors and paired metastasis did not show a clear effect
on GRPR mRNA expression, although these numbers were too small for reliable conclusions.
Comparison of GRPR and SSTR2mRNA levels of primary tumors and corresponding
metastases resulted in similar GRPR mRNA expression in primary tumors and paired regional
lymph nodes and distant metastases of the brain, lung, liver and ovaries. However, GRPR
mRNA expression was significantly higher in primary tumors compared to corresponding
metastases from other sites. Since this group is very diverse, containing metastases from dis-
tant lymph nodes, bone, uterus and metastases from the gastrointestinal tract, it is not possible
to draw solid conclusions. Regarding SSTR2, mRNA expression levels were significantly lower
in liver and ovarian metastases compared to the paired primary BC.
Combining our findings, both GRPR and SSTR2 are promising targets for nuclear imaging
and/or therapy in primary and metastatic ER-positive BC, but GRPR seems more suitable due
to its retained expression in the metastases. This finding is also supported by a previous study
by our group, in which we demonstrated GRPR expression in 48/50 BCs [6], while SSTR2 was
only expressed in 26/53 BCs (S.U. Dalm, C.H.M. van Deurzen, M. Melis, J.W. Martens and M.
de Jong, unpublished data, 2014).
Since a substantial portion of BC patients experience relapse with metastatic disease, it is
important to develop new treatment options for this late stage of disease. We showed that
receptor mRNA expression levels were similar in primary tumors and corresponding metasta-
ses in the majority of the cases, implying that targeting these receptors for disease monitoring
or therapy might improve BC patient care.
Biopsy material or excised tumors can be used to determine receptor expression by immu-
nohistochemistry, RNA in situ, in vitro autoradiography or RT-qPCR [21]. Disease monitor-
ing of receptor-positive tumors can then be performed by single photon emission computed
tomography/computer tomography (SPECT/CT), positron emission tomography (PET)/CT
or PET/magnetic resonance imaging using radioligands targeting these receptors. Also,
GRPR and SSTR2 in Breast Cancer Metastases
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dedicated breast PET cameras can be used. These dedicated cameras have improved sensitivity
and specificity compared to whole body PET, because of a restricted field of view, resulting in
higher cancer detection [22]. Furthermore, tumors can be treated with therapeutic radioli-
gands. Another option is to use GRPR or SSTR2 radioligands for visualization of sentinel node
metastases or as a guide for BC surgery (e.g. preoperative imaging, radioguided surgery) in
patients with receptor positive primary tumors [23, 24].
The next step would be to perform clinical studies to investigate the feasibility of imaging
primary tumors and metastases with radioligands targeting these receptors. One important
aspect is to study physiological uptake of the radioligands in other organs, since this is of great
importance for successful nuclear imaging and treatment. However, previous studies using
radioligands targeting these receptors on other tumor types did not report on any alarming
physiological uptake [5, 7].
Another potential interesting target for receptor mediated nuclear imaging and/or therapy
is chemokine c-x-c motif receptor 4 (CXCR4), since high CXCR4 expression was reported in
BC with high metastatic potential. Furthermore, radiotracers targeting the CXCR4 are
available and have been tested successfully pre-clinically and clinically. Unfortunately, the
CXCR4-targeted radiotracer available to us (Pentixafor) showed reduced affinity when labeled
with 111In, hampering in vitro autoradiography experiments. We could therefore only analyze
CXCR4 mRNA expression levels as described in S3 File.
Conclusion
The presented data indicates that nuclear based imaging and therapy has the potential to
improve BC patient care in primary as well as in metastatic disease, by targeting GRPR and
SSTR2. Both GRPR and SSTR2 radioligands, but especially GRPR radioligands, are promising
for imaging and treatment of ER-positive primary and metastatic BC.
Supporting Information
S1 File. Supplemental methods.
(DOCX)
S2 File. Supplemental table.
(DOCX)
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